Table 2.
Patient Characteristics at Study Entry
| a. ITT Population | ||||||||
|---|---|---|---|---|---|---|---|---|
| Patient Cohort | Age | Response to Frontline Rx (number) |
Cytogenetics (number) |
Performance Status | WBC ×109/L |
Platelets ×109/L |
Peripheral Blood Blasts % |
BM Blasts % |
| Overall | 58 (19 – 88) | Refractory 19 Relapsed 34 |
Favorable: 4 Intermediate: 28 Adverse: 17 |
1 (0 – 3) | 3.3 (.3 – 279.6) | 43 (5 – 659) | 14.5 (0 – 97) | 38 (4 – 100) |
| Group 1 | 63 (19 – 88) | Refractory 5 Relapsed 8 |
Favorable: 1 Intermediate: 8 Adverse: 3 |
1 (0 – 2) | 3.01 (1 – 279.6) | 45 (11 – 659) | 14 (0 – 87) | 26 (12 – 92) |
| Group 2 | 58 (25 – 81) | Refractory 6 Relapsed 15 |
Favorable: 1 Intermediate: 10 Adverse: 8 |
1 (0 – 2) | 3.6 (.3 – 84.7) | 27 (5 – 642) | 13 (0 – 92) | 45 (4 – 100) |
| Group 3 | 52 (25 – 76) | Refractory 8 Relapsed 11 |
Favorable: 2 Intermediate: 10 Adverse: 6 |
0 (0 – 3) | 2.9 (1.1 – 66.6) | 43 (8 – 361) | 23 (0 – 97) | 36 (8 – 89) |
Data is reported as Median, Min., Max., unless otherwise specified.
Cytogenetics – 4 patients have no available Cytogenetics data, Group 1 (n=1), Group 2 (n=2), Group 3 (n=1)
BM, bone marrow; WBC, white blood cell count